JP2021532063A5 - - Google Patents

Info

Publication number
JP2021532063A5
JP2021532063A5 JP2020567044A JP2020567044A JP2021532063A5 JP 2021532063 A5 JP2021532063 A5 JP 2021532063A5 JP 2020567044 A JP2020567044 A JP 2020567044A JP 2020567044 A JP2020567044 A JP 2020567044A JP 2021532063 A5 JP2021532063 A5 JP 2021532063A5
Authority
JP
Japan
Prior art keywords
groups
alkyl
antibody
cancer
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020567044A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532063A (ja
JP7390315B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035015 external-priority patent/WO2019232449A1/en
Publication of JP2021532063A publication Critical patent/JP2021532063A/ja
Publication of JP2021532063A5 publication Critical patent/JP2021532063A5/ja
Priority to JP2023196433A priority Critical patent/JP7753317B2/ja
Application granted granted Critical
Publication of JP7390315B2 publication Critical patent/JP7390315B2/ja
Priority to JP2025165244A priority patent/JP2026004432A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020567044A 2018-06-01 2019-05-31 スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法 Active JP7390315B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023196433A JP7753317B2 (ja) 2018-06-01 2023-11-20 スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
JP2025165244A JP2026004432A (ja) 2018-06-01 2025-10-01 スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862679672P 2018-06-01 2018-06-01
US201862679631P 2018-06-01 2018-06-01
US62/679,672 2018-06-01
US62/679,631 2018-06-01
US201862779324P 2018-12-13 2018-12-13
US62/779,324 2018-12-13
PCT/US2019/035015 WO2019232449A1 (en) 2018-06-01 2019-05-31 Splicing modulator antibody-drug conjugates and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023196433A Division JP7753317B2 (ja) 2018-06-01 2023-11-20 スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021532063A JP2021532063A (ja) 2021-11-25
JP2021532063A5 true JP2021532063A5 (cg-RX-API-DMAC7.html) 2022-06-06
JP7390315B2 JP7390315B2 (ja) 2023-12-01

Family

ID=66999916

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020567044A Active JP7390315B2 (ja) 2018-06-01 2019-05-31 スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
JP2023196433A Active JP7753317B2 (ja) 2018-06-01 2023-11-20 スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
JP2025165244A Pending JP2026004432A (ja) 2018-06-01 2025-10-01 スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023196433A Active JP7753317B2 (ja) 2018-06-01 2023-11-20 スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
JP2025165244A Pending JP2026004432A (ja) 2018-06-01 2025-10-01 スプライシング調節薬抗体-薬物コンジュゲート及びその使用方法

Country Status (18)

Country Link
US (6) US12172986B2 (cg-RX-API-DMAC7.html)
EP (1) EP3801632A1 (cg-RX-API-DMAC7.html)
JP (3) JP7390315B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210016375A (cg-RX-API-DMAC7.html)
CN (5) CN119405833A (cg-RX-API-DMAC7.html)
AU (2) AU2019277700C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020024549A2 (cg-RX-API-DMAC7.html)
CA (1) CA3099920A1 (cg-RX-API-DMAC7.html)
CL (8) CL2020003117A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020016137A2 (cg-RX-API-DMAC7.html)
IL (3) IL305431B2 (cg-RX-API-DMAC7.html)
JO (3) JOP20200268A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020012997A (cg-RX-API-DMAC7.html)
PE (1) PE20211220A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020500672A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202010341PA (cg-RX-API-DMAC7.html)
TW (1) TW202519520A (cg-RX-API-DMAC7.html)
WO (1) WO2019232449A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL320863A (en) 2017-10-02 2025-07-01 Visterra Inc Antibodies to CD138 and their uses
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
IL278740B2 (en) 2018-06-01 2024-01-01 Eisai R&D Man Co Ltd Methods for using splicing modulators
CN111655295B (zh) 2018-08-29 2024-05-28 荣昌生物制药(烟台)股份有限公司 抗her2抗体药物偶联物在治疗尿路上皮癌中的用途
CN120189526A (zh) 2018-12-13 2025-06-24 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
US20220098578A1 (en) 2019-01-31 2022-03-31 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
GB201905780D0 (en) * 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
BR112021025421A2 (pt) 2019-06-17 2022-02-01 Visterra Inc Moléculas de anticorpo humanizado para cd138 e os usos dos mesmos
WO2021090062A1 (en) 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
CA3164797A1 (en) * 2019-12-23 2021-07-01 Eisai R&D Management Co., Ltd. Method of producing eribulin based antibody-drug conjugate
US20230338564A1 (en) * 2020-03-31 2023-10-26 Orum Therapeutics, Inc. Neodegrader conjugates
WO2021247769A1 (en) 2020-06-02 2021-12-09 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
EP4161966A1 (en) * 2020-06-05 2023-04-12 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use
US20240043928A1 (en) 2020-11-04 2024-02-08 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
TW202306588A (zh) * 2021-05-21 2023-02-16 中國大陸商榮昌生物製藥(煙臺)股份有限公司 抗體-藥物結合物與免疫檢查點抑制劑組合用於治療泌尿上皮癌之用途
US20230348614A1 (en) * 2021-11-24 2023-11-02 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
WO2023131866A1 (en) 2022-01-05 2023-07-13 Eisai R&D Management Co., Ltd. Biomarkers for myelodysplastic syndrome (mds) and methods of using the same
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
CN115974976B (zh) * 2022-11-23 2024-06-04 华中科技大学 拮抗多肽及用于制备抗急性肾损伤药物的应用
LT4601703T (lt) 2023-04-18 2026-06-25 Astrazeneca Ab Konjugatai, apimantys atskeliamuosius jungtukus
IL327670A (en) 2023-10-11 2026-06-01 Antikor Biopharma Ltd Antibodies, conjugates, and uses thereof
CN122497691A (zh) * 2023-12-19 2026-07-31 百欧恩泰欧洲股份公司 Cfc1结合分子
AU2024404304A1 (en) * 2023-12-19 2026-05-21 BioNTech SE Cfc1 binding molecule
WO2025240362A1 (en) * 2024-05-13 2025-11-20 The Board Of Trustees Of The Leland Stanford Junior University Discovery of enpp3 as a cgamp hydrolase with a role in anti-cancer immunity

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
FI903489A7 (fi) 1988-11-11 1990-07-10 Medical Res Council Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 感染性の呼吸性疾患の治療方法
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
NZ322175A (en) 1995-11-10 1999-02-25 Elan Corp Plc Peptides which enhance transport across tissues and methods of identifying the same
EP0871490B1 (en) 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US7555503B1 (en) 2000-06-30 2009-06-30 Click Commerce, Inc. Method and apparatus for managing updates to a catalog
TWI312681B (en) 2001-02-01 2009-08-01 Novel physiologically active substance
CZ20033208A3 (en) 2001-04-26 2004-03-17 Biogen, Inc. Cripto blocking antibodies and uses thereof
TWI334866B (en) 2002-05-29 2010-12-21 Mercian Corp Novel physiologically active substances
RU2338741C2 (ru) 2002-07-31 2008-11-20 Мершан Корпорейшн Новые физиологически активные вещества
US7576204B2 (en) 2002-07-31 2009-08-18 Mercian Corporation Heterocyclic macrolide pharmaceutical agent, a method of producing the same and use of the same
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
ATE469985T1 (de) 2004-02-06 2010-06-15 Eisai R&D Man Co Ltd Verfahren zur untersuchung der empfindlichkeit einer krebszelle gegenüber einem antikrebsmittel
CA2556027C (en) 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック, インコーポレイテッド 抗体薬剤結合体および方法
KR20080080482A (ko) 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 eph 수용체 항체
CN101282967B (zh) 2005-10-13 2011-01-26 卫材R&D管理有限公司 普拉二烯内酯b和普拉二烯内酯d的全合成
WO2008016187A1 (en) 2006-08-02 2008-02-07 Eisai R & D Management Co., Ltd. Pladienolide target molecule, compound capable of binding to the target molecule, and screening method for the compound
PT2845866T (pt) 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
US7790887B2 (en) 2007-01-29 2010-09-07 Eisai R&D Management Co., Ltd. Macrolide compound in solid form, process for preparation thereof, and pharmaceutical composition containing the same
WO2008111464A1 (ja) 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. スプライシング異常を指標とする抗ガン剤の作用検定方法
WO2009008492A1 (ja) 2007-07-06 2009-01-15 Eisai R & D Management Co., Ltd. マクロライド系化合物の製造方法およびその製造中間体
US8653283B2 (en) 2009-04-17 2014-02-18 The Regents Of The University Of California Anticancer agents
JPWO2011074621A1 (ja) 2009-12-18 2013-04-25 株式会社医学生物学研究所 メソセリン(msln)に対する抗体及びその用途
KR20150006000A (ko) 2012-05-01 2015-01-15 제넨테크, 인크. 항-pmel17 항체 및 면역접합체
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物,偶联方法,及其用途
US20140069822A1 (en) 2012-09-10 2014-03-13 Antec Leyden B.V. Electrochemical reduction of disulfide bonds in proteinaceous substances and electrochemical cell for carrying out such reduction
US9155357B2 (en) 2012-09-11 2015-10-13 Nike, Inc. Automated strobel printing
MX340090B (es) * 2012-11-05 2016-06-23 Pfizer Analogos de spliceostatina.
US20140275010A1 (en) * 2013-03-12 2014-09-18 Guo Zhu Zheng Quaternary salts
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
US10195289B2 (en) 2013-07-31 2019-02-05 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
MX371455B (es) 2013-08-02 2020-01-28 Pfizer Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco.
EP3066470A4 (en) 2013-11-05 2017-05-31 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
SG11201603960XA (en) 2014-01-31 2016-07-28 Daiichi Sankyo Co Ltd Anti-her2 antibody-drug conjugate
KR20190072663A (ko) 2014-04-25 2019-06-25 리나트 뉴로사이언스 코프. 약물이 고도로 로딩된 항체-약물 접합체
RS58400B1 (sr) 2014-05-15 2019-04-30 Eisai R&D Man Co Ltd Jedinjenja pladienolid piridina i postupci primene
JP6349171B2 (ja) 2014-07-07 2018-06-27 ローム株式会社 ノイズ除去回路、タイミングコントローラ、ディスプレイ装置、電子機器、ソースドライバの制御方法
CN106604933B (zh) 2014-07-11 2021-08-10 文塔纳医疗系统公司 抗pd-l1抗体及其诊断用途
HUE049325T2 (hu) 2014-08-28 2020-09-28 Pfizer Stabilitás modulátor linker antitest-hatóanyag konjugátumokhoz történõ alkalmazásra
AU2016206475B2 (en) 2015-01-16 2021-11-04 City Of Hope Cell penetrating antibodies
HUE057285T2 (hu) 2015-04-13 2022-04-28 Pfizer Terápiás ellenanyagok és alkalmazásaik
WO2017011803A1 (en) * 2015-07-16 2017-01-19 Cellerant Therapeutics, Inc. Cysteine-substituted immunoglobulins
EP3344780B1 (en) 2015-09-01 2021-06-23 Eisai R&D Management Co., Ltd. Splice variants associated with neomorphic sf3b1 mutants
IL259198B2 (en) 2015-11-18 2023-04-01 Eisai R&D Man Co Ltd A solid form of paladinolide pyridine compound and methods of its use
US10689458B2 (en) 2015-11-30 2020-06-23 Pfizer Inc. Site specific HER2 antibody drug conjugates
ES2904593T3 (es) 2016-01-21 2022-04-05 Pfizer Anticuerpos monoespecíficos y biespecíficos para la variante III del receptor del factor de crecimiento epidérmico y CD3 y sus usos
MY199595A (en) 2016-03-02 2023-11-08 Eisai R&D Man Co Ltd Eribulin-based antibody-drug conjugates and methods of use
CN105669800B (zh) 2016-03-03 2017-12-15 湖南省农产品加工研究所 一种从柑橘中联合提取精油、果胶、橙皮苷、辛弗林和柠檬苦素的方法
CN117534764A (zh) 2016-06-06 2024-02-09 阿布泽纳(英国)有限公司 抗体、其用途及其缀合物
KR20220147719A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
CN111801353B (zh) 2017-10-13 2024-09-17 A&G药品公司 针对前列腺素f2受体抑制剂的单克隆抗体和缀合物及其用途
CA3096400A1 (en) 2018-04-09 2019-10-17 Eisai R&D Management Co., Ltd. Certain pladienolide compounds and methods of use
CA3096424A1 (en) 2018-04-12 2019-10-17 Eisai R&D Management Co., Ltd. Pladienolide derivatives as spliceosome targeting agents for treating cancer
IL278740B2 (en) 2018-06-01 2024-01-01 Eisai R&D Man Co Ltd Methods for using splicing modulators
CN119405833A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
CN120189526A (zh) 2018-12-13 2025-06-24 卫材R&D管理有限公司 荷伯希二烯抗体-药物缀合物及使用方法
WO2021090062A1 (en) 2019-11-07 2021-05-14 Eisai R&D Management Co., Ltd. Anti-mesothelin eribulin antibody-drug conjugates and methods of use
JP7821733B2 (ja) 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
EP4161966A1 (en) 2020-06-05 2023-04-12 Eisai R&D Management Co., Ltd. Anti-bcma antibody-drug conjugates and methods of use

Similar Documents

Publication Publication Date Title
JP2022512401A5 (cg-RX-API-DMAC7.html)
JP5925684B2 (ja) 抗gcc分子と関連組成物および方法
CN108026123B (zh) 用于偶联的亲水链接体
ES2874306T3 (es) Conjugados de anticuerpos y fármacos (CAF) que se unen a las proteínas 191P4D12
KR102023496B1 (ko) 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
US7067131B2 (en) Methods for using anti-MUC18 antibodies
ES2818575T3 (es) Reducción selectiva de anticuerpos con modificación de cisteínas
ES2795818T3 (es) Anticuerpos CD48 y conjugados de los mismos
CN106414465B (zh) 带电荷链接体及其在共轭反应上的应用
RU2018134331A (ru) Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения
JP2023500875A5 (cg-RX-API-DMAC7.html)
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP7570329B2 (ja) ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
JP7827624B2 (ja) 抗cea抗体-エキサテカン類似体複合体及びその医薬用途
EP3600444A1 (en) HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY
RU2014148162A (ru) Анти-pmel17 антитела и их иммуноконъюгаты
TW201905000A (zh) 含有抗globo h抗體之抗體-藥物共軛物及其用途
CN113453724B (zh) 基于磺酰基马来酰亚胺的连接子和相应的偶联物
JPWO2023033129A5 (cg-RX-API-DMAC7.html)
US20260021194A1 (en) Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload
JP2016511257A (ja) 癌の治療における抗gcc抗体−薬物複合体及びdna損傷剤の投与
NZ771328B2 (en) Splicing modulator antibody-drug conjugates and methods of use
RU2024115226A (ru) Конъюгаты антитела и лекарственного средства, содержащие модулятор сплайсинга на основе гербоксидиена, и способы их применения
NZ771328A (en) Splicing modulator antibody-drug conjugates and methods of use
US20260061066A1 (en) Anti-grp78 antibody, immunoconjugate and uses thereof